The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to account for the largest share and also register the highest CAGR during the forecast period.
According to the new market research report "North American Nuclear Medicine Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024", published by MarketsandMarkets™, the North American Radiopharmaceuticals Market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, at a CAGR of 4.1%.
Request Sample of Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108
The key factors driving the growth of this market are increasing incidence and prevalence of cancer & cardiac ailments and the initiatives to lessen the demand-supply gap of Mo-99.
Key Market Players
Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).
Cardinal Health (US) is one of the major players in the North American nuclear medicine market. Cardinal Health is a healthcare services company providing pharmaceutical and medical products & services to healthcare providers. Cardinal Health operates in the US, Canada, the British Virgin Islands, Malaysia, Singapore, the UK, Luxembourg, Thailand, Switzerland, Ireland, and Belgium through its 150 subsidiaries.
Curium (France) is another major player in the North American nuclear medicine market. Curium started its operations in 2017 through the union of two major players—IBA Molecular (France) and Mallinckrodt Pharmaceuticals (Ireland)—in the nuclear medicine market. Curium focuses on innovation, and it invested ~USD 3 million to build a new R&D laboratory
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108
GE Healthcare (US) has a huge network of radiopharmacies and a robust customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the North American nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Request for Custom Research @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1108
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/north-american-nuclear-medicine-radiopharmaceuticals-market.asp
Visit Our Website: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/north-american-nuclear-medicine-radiopharmaceuticals.asp
Global Pedicle Screw System Market guarantees you will
remain better informed than your competition. This study provides the broader
perspective of the market place with its comprehensive market insights and
analysis which eases surviving and succeeding in the market. Global Pedicle
Screw System market report through its market research helps improve and modify
products so that the necessary changes to the future products can be made and
more satisfaction is presented to the valuable customers.
Request for Free Sample Report @
https://www.marketsandmarkets.com/requestsample.asp?id=98811670
The Pedicle Screw Systems Market is expected to reach USD
724.23 million by 2023 from USD 538.64 million in 2018, at a CAGR of 6.1%.
The report analyzes and studies the major drivers,
restraints, opportunities, and challenges of the Pedicle Screw System Market in
North America, Europe, Asia Pacific, and the Rest of the World (RoW). The high incidence of sports injuries,
growing geriatric population, rising inclination of patients and hospitals
towards minimally invasive surgeries, technological advancements in arthroscopy
products, and an efficient reimbursement system in developed countries are some
of the factors driving the growth of the market.
The increasing incidence of spinal cord injuries, increasing
aging population, and technological advancements are major factors driving the
growth of the Pedicle Screw Systems Market.
Polyaxial pedicle screw systems are expected to account
for the largest market share
On the basis of product type, the Pedicle Screw Systems
Market is segmented into monoaxial, polyaxial, and other pedicle screw systems.
the polyaxial pedicle screw systems segment is expected to account for the
largest share of the global Pedicle Screw Systems Market. The large share of
this market segment can be attributed to the increasing prevalence of spinal
cord disorders and product launches.
Browse in-depth TOC on "Pedicle Screw Systems
Market"
66 - Tables
36 - Figures
110 - Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/pedicle-screw-system-market-98811670.html
Open surgery is estimated to account for the largest
share of the Pedicle Screw Systems Market
By surgery type, the Pedicle Screw Systems Market has been
segmented into open surgery and minimally invasive surgery. the open surgery
segment is expected to account for the largest share of the Pedicle Screw
Systems Market due to the rising geriatric population, increasing incidence of
spinal deformities, and technological advancements in spinal fusion surgeries.
The spinal degeneration segment is estimated to grow at
the highest CAGR during the forecast period
By indication, the market includes spinal degeneration,
spinal trauma, spinal deformities, and other indications. The spinal
degeneration segment is estimated to register the highest CAGR during the
forecast period. The high prevalence of degenerative spine disorders is
expected to result in a growing volume of surgical procedures performed.
North America is estimated to command the largest share
of the market
Based on region, the Pedicle Screw Systems Market is
segmented into North America, Europe, Asia Pacific, and the Rest of the World
(RoW). North America is expected to account for the largest share of the global
Pedicle Screw Systems Market.
Key
Market Players
Key players in the Pedicle Screw Systems Market include
DePuy Synthesis (US), Globus Medical (US), Zimmer Biomet (US), B. Braun (US),
Medtronic (Ireland), and Stryker (US).
Speak to Our Analyst and gain crucial industry insights
that will help your business grow:
https://www.marketsandmarkets.com/speaktoanalyst.asp?id=98811670
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth niche opportunities/threats which will impact 70% to 80% of
worldwide companies' revenues. Currently servicing 5000 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000 top
officers across eight industries worldwide approach MarketsandMarkets™ for
their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are
tracking global high growth markets following the "Growth Engagement Model
- GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors. MarketsandMarkets™
now coming up with 1,500 MicroQuadrants (Positioning top players across
leaders, emerging companies, innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets™ is determined to benefit more than
10,000 companies this year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets's flagship competitive intelligence and
market research platform, "Knowledge Store" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Transplant Diagnostics Industry Overview
The report "Transplant Diagnostics Marketby Technology (PCR, NGS, Sanger Sequencing), Product(Instrument, Reagent, Software), Application(HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User, & Region - Global Forecasts to 2028", is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period.
Organ transplants have gradually improved over the past 20 years and typically produce excellent results in children and young adults. However, the proportion of elderly transplant patients with comorbidities is increasing, posing a greater challenge. When compared to dialysis, renal transplants increase patient survival, and patients with liver, heart, or lung diseases that are incurable must receive life-saving transplants. The activity of solid organ transplant programmes has been steadily increasing, but it still falls short of global needs and varies greatly between nations. Transplanting solid organs is crucial for advanced and established medical systems.
Gather more insights about the market drivers, restrains and growth of the Global Transplant Diagnostics Market
Molecular assay technologies segment to register a significant growth rate over the forecast period of 2022-2028
Based on Technology, molecular assay technologies are segmented to witness the highest growth during the forecast period. Molecular assay technologies are segmented into PCR-Based molecular assays and sequencing-based molecular assays. PCR-based molecular assays are further segmented into Real-time PCR, Sequence-specific primer, Sequence-specific Oligonucleotide and other PCR-based molecular assays.
Sequence-specific Oligonucleotide is growing at the highest CAGR of 9.5%.
The Reagents & Consumables holds the largest share in the Product and Service segment of the Transplant diagnostic market.
The reagents and consumables is projected to reach USD 5,131.0 million from USD USD 3,265.2 million in 2022 with the CAGR of 7.8%.
Based on End users, the transplant diagnostic market is segmented into Hospitals and Diagnostic centers, Research & Academic Institutes and Independent reference laboratories. The Independent reference laboratories segment accounted for the largest share of the transplant diagnostic market. The growing number of organ transplant procedures and growing number of diagnostic labs across emerging countries are helping the independent diagnostic centers to hold the largest share.
North America to register major growth in the market during the forecast period
North America transplant diagnostic market is anticipated to register the highest growth over the forecast period of 2022 to 2028. North America accounted for the largest share of 45.5% of the transplant diagnostic market in 2022. This market is projected to reach USD 3.1 billion by 2028 from USD 2.0 billion in 2022, at a CAGR of 7.6% during the forecast period. North America holds 45.5% share of the total antimicrobial susceptibility testing market. The large share of North America can be attributed due to the growth in the geriatric population and the increase in infectious diseases., Asia-Pacific is expected to experience significant development.
Transplant Diagnostics Market Segmentation
This report categorizes the global transplant diagnostics market into following segments & sub-segments:
By Technology
By Product & Service
By Application
By transplant type
By End User
By Region
Market Share Insights
Key Companies profiled:
Some prominent players in the global Transplant Diagnostics market include
· Becton
· Dickinson and Company
· Biomerieux SA
· Bio-Rad Laboratories
· Inc.F-Hoffman-LA-Roche
· and Thermo fisher Scientific.
Order a free sample PDFof the Transplant Diagnostics Market Intelligence Study, published by MarketsandMarkets
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period. In 2019, Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), Epic Systems Corporation (US), and NextGen Healthcare (US) were some of the major players in the Ambulatory Surgical Centers market.
Key Market Players:
Some of the other prominent players operating in the Ambulatory Surgical Centers market are McKesson Corporation (US), GE Healthcare (US), Philips Healthcare (Netherlands), athenahealth, Inc. (US), Optum (US), Medical Information Technology, Inc. (MEDITECH) (US), eClinicalWorks (US), Advanced Data Systems Corporation (US), CureMD (US), HST Pathways (US), and Surgical Information Systems (US).
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182183086
Cerner Corporation (US) is one of the major players in the Ambulatory Surgical Centers market. The company has a diversified product portfolio, which includes a wide range of Ambulatory Surgical Centers IT products and services. Cerner’s position in the market is attributed to its active R&D activities and wide distribution footprint across the globe. To garner a larger share of the Ambulatory Surgical Centers market, the company continuously focuses on product launches and collaborations with other companies.
Allscripts Healthcare Solutions, Inc. (US) is one of the major players in the Ambulatory Surgical Centers market. Its dominance in the market can be attributed to its wide range of product offerings and its strong geographical footprint through strategic acquisitions and partnerships. Allscripts signed an agreement with Northwell Health for the development of next-generation, AI-powered electronic health records that would be used for better management of patient data among healthcare organizations. The company also focuses on R&D activities to develop its Ambulatory Surgical Centers that meet the customers’ demands.
Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=182183086
Recent Developments
Ambulatory Surgical Centers Market Advantages:
Get Special Pricing on Bundle Reports:
https://www.marketsandmarkets.com/RequestBundleReport.asp?id=182183086
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
The report "Parkinsons Disease
Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists,
MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies),
Patient Care Setting (Hospitals, Clinics) - Global Forecast",
Parkinson’s Disease DrugsMarket Overview, Demand, New
Opportunities & SWOT Analysis
The Parkinson’s Disease Drugs market
is being driven by the growth in aging population and the associated increase
in the prevalence of Parkinsons disease and government funding for research.
Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247
This report aims to provide insights into
the global Parkinson’s disease treatment market. It provides valuable
information on the market classification by drug class, distribution channels,
and patient care setting. Details on regional markets for these segments have
also been presented in this report. In addition, leading players in the market
are profiled to understand the strategies undertaken by them to be competitive
in this market.
The Parkinsons disease treatment market is
expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a
CAGR of 6.1%.
By drug class, the carbidopa/levodopa
segment is estimated to dominate the market in 2017
On the basis of drug class, the Parkinsons
disease therapeutic drugs market is segmented into carbidopa/levodopa, dopamine
receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other
drugs. In 2017, the carbidopa/levodopa segment is expected to account for the
largest share of the market. Carbidopa/levodopa drugs are more potent than most
other drug classes are hence widely used in the treatment of Parkinson’s
disease.
By distribution channel, the hospital
pharmacies segment is estimated to hold the largest share of the market in 2017
By distribution channel, the Parkinsons
disease therapeutic drugs market has been segmented into hospital pharmacies,
retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies
segment is expected to account for the largest share of the market. The large
share of this segment can primarily be attributed to the availability of a wide
range of drugs in these facilities and the increasing number of patient visits
to hospitals.
Browse complete Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
Hospitals to dominate the Parkinsons
disease treatment market during the forecast period
The Parkinsons disease treatment market is
classified by patient care settings into hospitals and clinics. In 2017, the
hospital segment is expected to command the largest share and is estimated to
grow at the fastest rate as compared to clinics segment. This market is mainly
driven by robust healthcare services provided in hospitals and the presence of
skilled neurologists in the hospitals.
Asia to offer lucrative growth
opportunities
By region, the global Parkinsons disease
treatment market is segmented into North America, Europe, Asia, and the Rest of
the World (RoW). While Europe is expected to hold the largest share of the
market in 2017, Asia is expected to grow at the highest CAGR during the
forecast period. Increasing number of players in the region and the rising
aging population are some major factors driving the high growth of this
regional segment.
Some of the major players operating in the
Parkinsons disease treatment market include Teva (Israel), Novartis AG
(Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim
(Germany), Impax Laboratories (US),
Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium),
Valeant Pharmaceuticals (Canada), and Acadia (US).
Tevais one
of the key players in the Parkinson’s disease treatment market. The company
focuses on organic and inorganic strategies to strengthen its position in the
Parkinson’s disease treatment market. For instance, in 2015, the company
entered into an agreement with Takeda pharmaceutical company to commercialize
rasagiline tablets in the Japan.
Moreover, the company received FDA approval for AZILECT drug to treat
all stages of the Parkinson’s disease
Access Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=47265247
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B
research on 30,000 high growth niche opportunities/threats which will impact
70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers
worldwide including 80% of global Fortune 1000 companies as clients. Almost
75,000 top officers across eight industries worldwide approach
MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at
MarketsandMarkets™ are tracking global high growth markets following the
"Growth Engagement Model – GEM". The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify most
important customers, write "Attack, avoid and defend" strategies,
identify sources of incremental revenues for both the company and its
competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s flagship competitive
intelligence and market research platform, "RT" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Factors such as
increasing investments in healthcare infrastructural development, technological
innovations in ICU beds, increasing number of beds in private hospitals, and
increasing volume of chronic care patients are expected to drive the growth of
the medical beds market in the coming years. On the other hand, the declining
number of beds in public hospitals may limit market growth to a certain extent.
The growing trend of home care is expected to provide a wide range of
opportunities to players in the Medical Beds Market.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=171671404
Market Dynamics
Drivers
Restraints
Opportunities
Based on usage, the medical beds market is segmented into major four
categories— acute care, psychiatric care and bariatric care, long-term care,
and other beds (maternity and rehabilitative beds). The long-term care segment
is expected to have the fastest-growing market during the forecast period owing
to the increasing number of patients requiring long-term care.
Read More about Medical Beds Market:
https://www.marketsandmarkets.com/Market-Reports/hospital-beds-market-171671404.html
On the basis of type, the medical beds market is segmented into— manual
beds, semi-electric beds, and electric beds. The electric beds segment is
expected to dominate the medical beds market in 2017. The growing obesity rate
is the major factor driving the demand for electric beds, as these are
essential medical equipment in bariatric care. Moreover, the presence of
favorable reimbursement policies in major markets such as the U.S. is also
expected to support the growth of the electric beds market. For instance,
Medicare provides a reimbursement of 7.5% on the purchase of new electric beds
which can be used in home care settings. Such factors have increased the
adoption rate of electric beds in home care and elderly care settings in
developed regions such as the U.S.
Geographically, Europe is
expected to account for the largest share of the global medical beds market in
2017, followed by North America. Compared to mature markets, the Asia-Pacific
region is expected to grow at the highest CAGR in the forecast period. Growth
in this regional segment is propelled by the growing healthcare infrastructure,
rising number of contract manufacturing organizations (CMOs), and increasing
number of bariatric population requiring care.
Major players operating in
the medical beds market include Stryker Corporation (U.S.), Hill-Rom Holding,
Inc. (U.S.), Getinge Group (Sweden), and Invacare Corporation (U.S.).
Talk
To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=171671404
The global cell therapy technologies market is projected to
reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6%
during the forecast period. Market growth is driven mainly by increasing
research in regenerative medicine along with stem cell research, cancer
research, and cell biology research.
Request for Sample PDF Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978
The global cell therapy technologies market is consolidated.
The prominent players operating in this market include Thermo Fisher
Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza
Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson
and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US),
Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine
Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany),
RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics,
Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI
Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology
(China), and Wilson Wolf Manufacturing Corporation (US).
Thermo Fisher Scientific
Thermo Fisher Scientific offers a complete and integrated
portfolio of solutions and services for clinical science, laboratory research,
and analysis. It operates in four business segments—Life Sciences Solutions,
Analytical Instruments, Specialty Diagnostics, and Laboratory Products and
Services. Its Life Sciences Solutions segment offers a wide range of reagents,
instruments, and consumables used in biological and medical research, discovery
and production of new drugs and vaccines, as well as the diagnosis of diseases.
Merck KGaA
Merck operates through three business segments, namely,
Healthcare, Life Science, and Performance Materials. The Life Science segment
offers life science products and services for research and diagnostic purposes.
Merck offers products in the cell therapy technologies market through its Life
Science segment.
Danaher Corporation
Danaher Corporation operates through three strategic
segments—Environmental and Applied Solutions, Life Sciences, and Diagnostics.
The Diagnostics segment offers a wide range of products through its key
brands—SCIEX, Beckman Coulter, Leica Biosystems, Leica Microsystems,
Radiometer, and Cepheid. Beckman Coulter and Cytiva, subsidiaries of Danaher
Corporation, cater to the cell therapy technologies market. Beckman develops,
manufactures, and markets products in automation, diagnostics, and chemistry.
Browse Complete Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/cell-therapy-technologies-market-213334978.html
The Asia Pacific region is the fastest-growing region of
the cell therapy technologies market
The Asia Pacific is estimated to be the fastest-growing
segment of the market. The growth of the cell therapy technologies market of
the region is mostly driven by their low labor and manufacturing costs, which
has drawn huge investments by biopharma giants to these countries.
Recent Developments
·
Thermo Fisher Scientific launched the first
T-cell medium designed specifically for allogeneic cell therapy workflows.
·
Danaher acquired the Biopharma business from
General Electric Company's Life Sciences division. The acquisition has led to
the formation of a new business named Cytiva, a standalone operating company
within Danaher's Life Sciences segment.
Buy-Now this Premium Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=213334978
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B
research on 30,000 high growth niche opportunities/threats which will impact
70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers
worldwide including 80% of global Fortune 1000 companies as clients. Almost
75,000 top officers across eight industries worldwide approach
MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at
MarketsandMarkets™ are tracking global high growth markets following the
"Growth Engagement Model – GEM". The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify most important
customers, write "Attack, avoid and defend" strategies, identify
sources of incremental revenues for both the company and its competitors.
MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies, innovators, strategic players)
annually in high growth emerging segments. MarketsandMarkets™ is determined to
benefit more than 10,000 companies this year for their revenue planning and
help them take their innovations/disruptions early to the market by providing
them research ahead of the curve.
MarketsandMarkets’s flagship competitive
intelligence and market research platform, "Knowledgestore" connects
over 200,000 markets and entire value chains for deeper understanding of the
unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Particle TherapyIndustry Overview
Global particle
therapy market is projected to reach USD 1,004 million by 2027 from USD 677
million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137
Market growth is driven by factors such as growing adoption
of particle therapy in clinical trials and the increasing number of particle
therapy centers worldwide. Emerging markets are China India, Brazil, and South
Africa are showing lucrative growth opportunities to market.
Covid-19 Impact on Economic Scenario in Particle Therapy
Market
Globally, the outbreak of COVID-19 has impacted every aspect
of the medical device industry, including particle therapy devices. From region
to region, there is considerable variation in the management of particle
therapy procedures during the COVID-19 pandemic. The particle therapy market is
expected to be impacted due to the temporary postponement of various elective
surgeries as governments and authorities seek to ensure the availability of
resources for COVID-19 patients.
Particle Therapy Market Segmentation
Pediatric cancer defined for the largest share in the
particle therapy market by cancer type
Based on cancer type, the particle therapy market is
segmented into prostate cancer. pediatric cancer, lung cancer, breast cancer,
head & neck cancer, and other cancers. The pediatric cancer segment is
holds the largest share of 24.8% of the particle therapy market in 2021 with
CAGR of 10.4% during the forecast period.
Products such as cyclotron accounted for the largest
share in the particle therapy market by product type
Based on products & services, the particle therapy
market is segmented into products and services. In 2021, products are estimated
to account for the largest share of 78.6% of the particle therapy market.
Based on system, multi-room systems holds the largest
share in the particle therapy
Based on the system, the particle therapy market is
segmented into single-room and multi-room particle therapy systems. The
multi-room systems segment is expected to account for the largest share (67.8%)
of the particle therapy market.
Particle Therapy Regional Outlook
Key Companies Profile & Market Share Insights
Prominent players in the particle therapy market include
Varian Medical Systems, Inc. (US), IBA Worldwide (EU), Mevion Medical Systems
(US), Provision Healthcare, LLC (US), Sumitomo Heavy Industries, Ltd. (Japan),
Hitachi, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), Protom International,
Inc. (US), Advanced Oncotherapy PLC. (EU), and Danfysik A/S (Denmark)
IBA is one of the leading players in the particle
therapy market. Its Proton Therapy segment offers Proteus PLUS, a treatment
room solution, and Proteus ONE, a single-room cancer treatment solution.
Order
a free sample PDFof the Particle TherapyMarket Intelligence Study, published by MarketsandMarkets.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth niche opportunities/threats which will impact 70% to 80% of
worldwide companies’ revenues. Currently servicing 7500 customers worldwide including
80% of global Fortune 1000 companies as clients. Almost 75,000 top officers
across eight industries worldwide approach MarketsandMarkets™ for their
painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are
tracking global high growth markets following the "Growth Engagement Model
– GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors.
MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies, innovators, strategic players)
annually in high growth emerging segments. MarketsandMarkets™ is determined to
benefit more than 10,000 companies this year for their revenue planning and
help them take their innovations/disruptions early to the market by providing
them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and
market research platform, "Knowledgestore" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Growth in this market is driven mainly by the rising
prevalence of lymphoma & myeloma cancers, growing focus on personalized
medicine, and increasing collaborations for developing assays.
Hemato oncology is typically referred to as the science
associated with the treatment, diagnosis, and prevention of blood-related
diseases and cancers.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877
Market Segmentation
Based on product & services, the market is
segmented into assay kits and services. In 2018, the services segment accounted
for the largest share of the product & services segment in the hemato
oncology testing market. The large share of this segment can be attributed to
the rising prevalence of hematologic cancers and increasing aging population.
Based on end-user, the hemato-oncology testing market
has been segmented into four types, i.e., clinical laboratories, hospitals,
academic & research institutes, and other end-users. Other end-users
include CROs and pharmaceutical & biotechnological companies. Clinical
laboratories accounted for the largest share of the market in 2018. This
segment is expected to grow at the highest rate in the coming years. This is
mainly due to the presence of advanced diagnostic equipment such as analyzers
and the presence of skilled professionals to perform these tests.
Regional Analysis
North America accounted for the largest share of the hemato
oncology testing market in 2018. The large share of this segment can primarily
be attributed to the high incidences of hematologic cancer, aging population,
awareness regarding advanced treatment methods, and the strong presence of
industry players in the region. These trends are likely to drive market growth
during the forecast period.
Key Market Players
Some of the leading players in the hemato oncology testing
market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories
(US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad
Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland),
Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US),
ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).
Get Data as per your Format and Definition | REQUEST FOR
CUSTOMIZATION @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877
Expected Revenue Growth:
[116 Pages Report] The hemato oncology testing market is
projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a
CAGR of 14.8% during the forecast period.
F. Hoffmann-La Roche Ltd. (Switzerland) was the
leading player in the hemato-oncology testing market in 2018. The company
offers a full range of tests for the diagnosis of hemato-oncology cancers, such
as leukemia, lymphoma, and myeloma, among others.
Intraoperative Radiation Therapy Market Trends:
Global intraoperative radiation therapy market is projected
to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4%
during the forecast period. The technological advancements such as the
introduction of mobile IORT system, rising incidence of cancer, and advantages
offered by IORT over conventional radiotherapy are the major factors driving
the growth of the global intraoperative radiation therapy market.
Get Sample PDF: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083
Key Market Players of Intraoperative Radiation
Therapy Market:
ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler
(Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus
Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton,
Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical
Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems
Ltd. (UK)
ZEISS is among the pioneer companies that combined
surgery with radiotherapy to develop and introduce intraoperative radiation
therapy to the cancer treatment field. The flagship product of the company,
INTRABEAM, is one of the most widely used IORT products across the globe.
INTRABEAM is a revolutionary, intraoperative form of radiation therapy for
early-stage breast cancers.
COVID-19 Impact on the global Intraoperative radiation
therapy market
The intraoperative radiation therapy market was
significantly impacted by the COVID-19 pandemic. Various screening, diagnostic,
and surgical procedures were restricted or postponed at hospitals and cancer
treatment centers, which resulted in disruptions in the cancer diagnosis as
well as treatment market. The pandemic also impacted the availability of
healthcare resources. Major regulatory authorities across the globe, such as
the CDC, WHO, MHRA, TGA, and EMA, have identified cancer patients at a greater
risk of contracting coronavirus disease than healthy adults.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083
Opportunity: Growing applications of IORT
Over the years, IORT has found significant applications as a
breast-conserving treatment. Technological advancements in this field, coupled
with the growing applications of IORT, has resulted in the increasing
collaboration between a large number of manufacturers and research institutes to
conduct clinical trials to study the applications and efficacy of IORT for
other cancer types.
Recent Developments
·
Elekta AB launched Geneva, a universal
gynecological applicator for brachytherapy.
·
Varian acquired Cancer Treatment Services
International (CTSI), a US-based oncology solutions division that provides
cancer care professional services to healthcare providers worldwide. The
acquisition expanded Varian’s access to technology-driven cancer care .
Speak to our analyst for a discussion on the above findings:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245000083
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth niche opportunities/threats which will impact 70% to 80% of
worldwide companies' revenues. Currently servicing 7500 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers
across eight industries worldwide approach MarketsandMarkets™ for their
painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are
tracking global high growth markets following the "Growth Engagement Model
- GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors. MarketsandMarkets™
now coming up with 1,500 MicroQuadrants (Positioning top players across
leaders, emerging companies, innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets™ is determined to benefit more than
10,000 companies this year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets's flagship competitive intelligence and
market research platform, "Knowledgestore" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441